Search results for "ADJUSTED LIFE-YEARS"

showing 4 items of 4 documents

Cultural adaptation of the Smiling is Fun program for the treatment of depression in the Ecuadorian public health care system: A study protocol for a…

2021

Background Depression is one of the world's major health problems. Due to its high prevalence, it constitutes the first cause of disability among the Americas, where only a very low percentage of the population receives the adequate evidence-based psychological treatment. Internet-Based Interventions (IBIs) are a great alternative to reduce the treatment gap for mental disorders. Although there are several studies in low-and middle-income countries proving IBIs' feasibility and acceptability, there is still little evidence of the effectiveness in diverse social and cultural contexts such as Latin America. Methods Two studies will be described: Study 1 is focused on the cultural adaptation o…

ICD-10 International Classification of Diseases-10GerontologyRCT Randomized Control Trial050103 clinical psychologyOASIS Overall Anxiety Severity and Impairment ScalePsychological interventionAPOI Attitudes Towards Psychological Online Interventionslaw.inventionCultural adaptation0302 clinical medicineCEQ Credibility and Expectancy QuestionnaireRandomized controlled trialODSIS Overall Depression Severity and Impairment Scalelaw030212 general & internal medicineCSQ Client Satisfaction QuestionnaireDepression (differential diagnoses)CRQ Cultural Relevance Questionnaireeducation.field_of_studylcsh:T58.5-58.64Depressionlcsh:Information technology05 social sciencesIBIs Internet-Based InterventionsTiC-P Trimbos/iMTA Questionnaire on Costs on Psychiatric IllnessesSPIRIT Recommendations for Interventional TrialsM.I.N.I. 5.0 MINI International Neuropsychiatric Interview 5.0PC Primary CareQALYs Quality-Adjusted Life-YearsdepressionRandomized Controlled TrialAnxietyRCI Reliable Change Indexmedicine.symptomPsychologyPHQ-9 Patient Health Questionnaire-9WL Waiting Listlcsh:BF1-990PopulationHealth InformaticsContext (language use)cultural adaptationGAD-7 Generalized Anxiety Disorder-703 medical and health sciencesPHC Public Health CareQuality of life (healthcare)EBPTs Evidence-Based Psychological TreatmentsIntervention (counseling)medicine0501 psychology and cognitive sciencesBDI-II Beck Depression Inventory-IIAQoL-6D Assessment of Quality of Life 6 DimensionsMCAR Missing Completely at Randompublic health careeducationPublic Health CareInternet-based interventionFull length ArticleSUS System Usability ScaleLatin Americalcsh:PsychologyWAI-TECH-SF Working Alliance Inventory for Online Intervention-Short Formrandomized controlled trialICERs Incremental Cost-Effectiveness RatiosPANAS Positive and Negative Affect ScheduleE-SF Ecuadorian Cultural Version of Smiling is FunCONSORT Consolidated Standards of Reporting TrialsInternet Interventions
researchProduct

The global burden of cancer attributable to risk factors, 2010–19 : A systematic analysis for the Global Burden of Disease Study 2019

2022

Background: Understanding the magnitude of cancer burden attributable to potentially modifiable risk factors is crucial for development of effective prevention and mitigation strategies. We analysed results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 to inform cancer control planning efforts globally. Methods: The GBD 2019 comparative risk assessment framework was used to estimate cancer burden attributable to behavioural, environmental and occupational, and metabolic risk factors. A total of 82 risk-outcome pairs were included on the basis of the World Cancer Research Fund criteria. Estimated cancer deaths and disability-adjusted life-years (DALYs) in 20…

MaleDEATHSDALY cancer risk factorsMedizinsystematic analysisGlobal HealthRisk AssessmentCancer preventionGlobal Burden of DiseaseRC0254Risk-attributable cancer deathsSDG 3 - Good Health and Well-beingRA0421Risk FactorsRA0421 Public health. Hygiene. Preventive MedicineQuality-Adjusted Life YearNeoplasmscancerHumansGlobal Burden of Disease StudyUKMedicine(all)MCCRC0254 Neoplasms. Tumors. Oncology (including Cancer)Risk FactorSmokingCOVID-193rd-DASGeneral MedicineDisability-adjusted life-yearsSOCIAL DETERMINANTSRisk assessmentsrisk factorCardiovascular and Metabolic Diseases3121 General medicine internal medicine and other clinical medicineOBESITYCancer burden/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingNeoplasmFemaleLIFE-STYLEQuality-Adjusted Life YearsHEALTHRAHumanRC
researchProduct

Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 20…

2020

Artículo con numerosos autores. Sólo se hace referencia al primero que coincide con el de la UAM y al colectivo

MaleRespiratory diseasesRespiratory Tract DiseasesDiseaseChronic respiratory diseasesGlobal Burden of DiseasePulmonary Disease Chronic Obstructive0302 clinical medicineCost of Illness11. SustainabilityMETABOLIC RISKSEPIDEMIOLOGY030212 general & internal medicineChildCause of deathAged 80 and overCOPDDALYChronic obstructive pulmonary diseaseMortality rateRespiratory disease1. No povertyAge FactorsMiddle AgedDeath causes3. Good healthPREVALENCEHealth risksChild PreschoolCOMPARATIVE RISK-ASSESSMENTFemaledeath and disability worldwideQuality-Adjusted Life YearsTERRITORIESBURDENgrowth in absolute numbersPulmonary and Respiratory MedicineAdultADJUSTED LIFE-YEARSHealth burdensAdolescentMedicina195 COUNTRIESchronic respiratory diseasesArticle1117 Public Health and Health Services03 medical and health sciencesYoung AdultLife ExpectancySex FactorsBurden of Disease Respiratory diseaseSarcoidosis PulmonaryEnvironmental healthmedicineDisability-adjusted life yearHumansCOPDEXPOSURERisk factorMortalityAgedper-capita basisbusiness.industryDISABILITYInfant NewbornInfant1103 Clinical Sciencesasthmamedicine.diseaseAsthmaYears of potential life lost030228 respiratory systemRisk factors13. Climate actionSystematic analysesChronic DiseaseINJURIESHuman medicinePneumoconiosisMorbiditybusinessLung Diseases Interstitial1199 Other Medical and Health Sciences
researchProduct

Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort

2017

We evaluated the cost-effectiveness of two alternative direct-acting antiviral (DAA) treatment policies in a real-life cohort of hepatitis C virus–infected patients: policy 1, “universal,” treat all patients, regardless of fibrosis stage; policy 2, treat only “prioritized” patients, delay treatment of the remaining patients until reaching stage F3. A liver disease progression Markov model, which used a lifetime horizon and health care system perspective, was applied to the PITER cohort (representative of Italian hepatitis C virus–infected patients in care). Specifically, 8,125 patients naive to DAA treatment, without clinical, sociodemographic, or insurance restrictions, were us…

hepatitis C virusPediatricsCost effectivenessViral HepatitisAdult; Aged; Aged 80 and over; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Health Policy; Hepatitis C; Humans; Middle Aged; Young Adult; Models Economic; HepatologyCost-Benefit AnalysisDirect-acting antiviralAdult; Aged; Aged 80 and over; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Health Policy; Hepatitis C; Humans; Middle Aged; Young Adult; Models EconomicCohort StudiesLiver disease0302 clinical medicineModelsHealth careantiviral therapy80 and overincremental cost-effectiveness ratiohealth care economics and organizationsHCV cost -effectivenessAged 80 and overDirect-acting antiviral hepatocellular carcinoma hepatitis C virus incremental cost-effectiveness ratio interferon quality-adjusted life-years sustained virological response willingness to payCost–benefit analysis030503 health policy & servicesquality-adjusted life-yearsHealth PolicyHepatitis Chepatocellular carcinomainterferonMiddle AgedHepatitis CModels EconomicAdult; Aged; Aged 80 and over; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Health Policy; Hepatitis C; Humans; Middle Aged; Young Adult; Models Economic; Hepatology; HCV; antiviral therapy; cost-effectiveness; real-life cohortCohortHCV030211 gastroenterology & hepatologyOriginal Articlesustained virological response0305 other medical scienceCohort studyHumanAdultmedicine.medical_specialtyEconomicAntiviral AgentsNO03 medical and health sciencesYoung Adultreal-life cohortmedicineHumansCost-Benefit Analysicost-effectivenessHealth policyAgedAntiviral AgentHepatologybusiness.industryOriginal Articlesmedicine.diseaseSurgeryCohort Studiebusinesswillingness to pay
researchProduct